Polar Asset Management Partners’s Travere Therapeutics TVTX Stock Holding History

Polar Asset Management Partners’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-16,958	Closed	-$304K	–	710
2025 Q1	$304K	Buy	+16,958	New	+$344K	0.01%	350
2023 Q3	–	Sell	-230,965	Closed	-$3.55M	–	977
2023 Q2	$3.55M	Sell	230,965 -567,225	-71%	-$10.3M	0.06%	372
2023 Q1	$18M	Buy	798,190 +480,900	+152%	+$10.2M	0.27%	92
2022 Q4	$6.67M	Sell	317,290 -25,000	-7%	-$530K	0.08%	339
2022 Q3	$8.43M	Sell	342,290 -240,410	-41%	-$6.21M	0.1%	313
2022 Q2	$14.1M	Buy	582,700 +491,500	+539%	+$12.4M	0.16%	173
2022 Q1	$2.35M	Buy	+91,200	New	+$2.42M	0.03%	605
2021 Q4	–	Sell	-257,500	Closed	-$6.24M	–	1517
2021 Q3	$6.24M	Buy	+257,500	New	+$4.73M	0.06%	346

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Polar Asset Management Partners's TVTX Position: Q2 2025 in Review

Polar Asset Management Partners sold out of Travere Therapeutics (TVTX) in Q2 2025, closing a stake of 16,958 shares — an estimated $304K sold.

Polar Asset Management Partners first reported a position in TVTX in Q3 2021 and held it in 8 quarters. The position peaked at $18M in Q1 2023. 211 funds tracked by Wall St. Rank hold TVTX as of Q2 2025.

Polar Asset Management Partners reported no remaining Travere Therapeutics position as of Q2 2025 after selling out during the quarter.
Polar Asset Management Partners sold 16,958 Travere Therapeutics shares in Q2 2025, an estimated $304K.
Polar Asset Management Partners first reported a position in Travere Therapeutics in Q3 2021 and held it in 8 quarters.
Polar Asset Management Partners's Travere Therapeutics position peaked at $18M in Q1 2023.
211 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2025.

Based on Polar Asset Management Partners's 13F filing for Q2 2025, filed 14 Aug 2025.